This paper is aimed at studying the usefulness of prostate-specific antigen (PSA) screening for patients with end-stage renal disease (ESRD) and also to assess if the incidence of prostate cancer is higher in this group of patients. This evidence concerns the gene KLK3 and stage 5 chronic kidney disease.